On July 2, 2025, Liminatus Pharma, Inc. announced a partnership with Samda Biolab and INNOCS AI to develop a new blood test for early pancreatic cancer detection, showing over 95% sensitivity and 99% specificity based on a study of 1,086 subjects. This collaboration aims to enter the $3 billion pancreatic cancer diagnostics market and enhance the company's position in precision oncology.